EKOS Pulmonary Embolism Forum 2022 Hong Kong
Boston Scientific is committed to helping practitioners to learn more about Pulmonary Embolism: how to diagnose it, how to treat it, and when it’s right to intervene.
Hear the expert Pr. Andrew Sharp discussing on the effectiveness of EKOS to reverse RV dysfunction and hemodynamic instability, and its association with low risk of bleeding and mortality in Intermediate to high-risk Pulmonary Embolism patients.
KNOCOUT PE Registry Prospective Cohort: 3-Month Data
KNOCOUT PE registry represents the single largest prospective data set in interventional PE treatment to-date, adding evidence to the already most studied device in the PE space. The registry included a wide range of patients with intermediate-high and high-risk PE, showing that contemporary clinical practices are moving to low-dose, shorter duration OPTALYSE protocols and with it comes the benefit of both sustained efficacy and an improved safety profile.
Hi-PEITHO Trial: Patient enrollment gets underway
The largest randomised controlled trial on Intervention vs Anticoagulation in Pulmonary Embolism.
We are pleased to see the official start to the HI-PEITHO trial with the first patient enrollment. HI-PEITHO is the largest, most rigorous trial in the PE space intended to address critical gaps in PE clinical evidence. This trial reflects Boston Scientific’s investment and commitment to providing the highest level of scientific evidence to ultimately help guide clinical practice.
-Dr. Michael R. Jaff, BSC
Ekos™ Endovascular System
Higher-risk Pulmonary Embolism Thrombolysis Study
Introducing the Hi-PEITHO randomised controlled trial for the EKOS™ Endovascular System. The study is the first to compare interventional therapy in combination with anticoagulation to anticoagulation alone for the treatment of pulmonary embolism.
Pulmonary Embolism and COVID-19 | How to handle this new paradigm?